Jupiter Topco LLC Buys New Stake in Baxter International Inc. $BAX

Jupiter Topco LLC purchased a new position in Baxter International Inc. (NYSE:BAX) during the 2nd quarter, Holdings Channel.com reports. The firm purchased 237,683 shares of the medical instruments supplier’s stock, valued at approximately $5,066,000.

A number of other hedge funds also recently bought and sold shares of the business. Covestor Ltd lifted its position in Baxter International by 9.5% during the fourth quarter. Covestor Ltd now owns 8,014 shares of the medical instruments supplier’s stock valued at $153,000 after purchasing an additional 695 shares during the last quarter. Bruce G. Allen Investments LLC raised its position in shares of Baxter International by 22.8% during the 4th quarter. Bruce G. Allen Investments LLC now owns 4,452 shares of the medical instruments supplier’s stock valued at $85,000 after buying an additional 827 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of Baxter International by 5.7% in the 4th quarter. Jump Financial LLC now owns 15,968 shares of the medical instruments supplier’s stock valued at $305,000 after acquiring an additional 854 shares during the last quarter. Nicholas Hoffman & Company LLC. grew its position in Baxter International by 2.1% in the fourth quarter. Nicholas Hoffman & Company LLC. now owns 46,913 shares of the medical instruments supplier’s stock worth $897,000 after acquiring an additional 943 shares in the last quarter. Finally, LRI Investments LLC increased its stake in Baxter International by 48.2% during the fourth quarter. LRI Investments LLC now owns 3,006 shares of the medical instruments supplier’s stock worth $57,000 after acquiring an additional 978 shares during the last quarter. Hedge funds and other institutional investors own 90.19% of the company’s stock.

Baxter International Trading Down 0.2%

Shares of NYSE BAX opened at $26.08 on Tuesday. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95. The business’s 50 day moving average price is $24.37 and its 200-day moving average price is $20.57. Baxter International Inc. has a fifty-two week low of $15.73 and a fifty-two week high of $30.00. The company has a market cap of $13.48 billion, a price-to-earnings ratio of -12.60, a PEG ratio of 3.96 and a beta of 0.59.

Baxter International (NYSE:BAX) last issued its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $2.80 billion. During the same period last year, the company earned $0.59 EPS. Baxter International’s quarterly revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. On average, sell-side analysts expect that Baxter International Inc. will post 2.04 earnings per share for the current year.

Baxter International Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Stockholders of record on Friday, August 28th will be given a dividend of $0.01 per share. This represents a $0.04 annualized dividend and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International’s dividend payout ratio (DPR) is -1.93%.

Analyst Ratings Changes

Several research firms have recently issued reports on BAX. Stifel Nicolaus raised their price objective on Baxter International from $19.00 to $24.00 and gave the company a “hold” rating in a research note on Tuesday, July 28th. TD Cowen increased their price target on Baxter International from $20.00 to $24.00 and gave the company a “hold” rating in a report on Monday, July 27th. Citigroup upgraded Baxter International from a “sell” rating to a “neutral” rating and increased their price target for the company from $17.00 to $28.00 in a report on Friday, July 31st. Wall Street Zen raised shares of Baxter International from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Finally, The Goldman Sachs Group boosted their price objective on shares of Baxter International from $19.00 to $21.00 and gave the company a “neutral” rating in a research report on Wednesday, July 15th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Baxter International currently has a consensus rating of “Hold” and a consensus target price of $22.45.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.